This Clinical Guideline has been developed by the Monash Women’s Maternity Guideline Development Group in consultation with Anaesthetics and Pharmacy and is underpinned mainly by the (2014) Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) evidence based guidelines.¹

**Target population for the guideline**
Pregnant and post-partum women who present with or develop hypertensive disorders, pre-eclampsia and/or eclampsia.

**Target users of the guideline**
Monash Health medical staff and midwives.

**Background**
Hypertension (defined as a systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg) is a common medical problem encountered in pregnancy. It can be classified into four categories:

1. Pre-eclampsia/eclampsia
2. Gestational hypertension
3. Chronic hypertension; and
4. Pre-eclampsia superimposed on chronic hypertension.

The definition and diagnostic criteria for each condition is based on the gestation at diagnosis and the presence of co-existing haematological, biochemical and/or feto-placental abnormalities. More details regarding these conditions can be found in the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) Guideline.¹

**Pre-eclampsia** is a unique condition to human pregnancy, diagnosed after 20 weeks gestation. It is a multi-system disorder characterised by hypertension with associated involvement of one or more organ systems such as haematological, renal, hepatological, neurological and/or feto-placental compromise. Pre-eclampsia can be seen to affect 3-8 % of all pregnancies¹,²,¹⁰-¹² and can also develop, or continue into the post-natal period.

Risk factors for pre-eclampsia include a previous personal or family history, co-existing medical conditions (e.g. diabetes type 1 or type 2, antiphospholipid syndrome, renal disease, systemic lupus erythematosus), multiple pregnancy, nulliparity and obesity. In women with a moderate to high risk of developing pre-eclampsia, prophylaxis with low dose aspirin (150 mg/nocte)¹-³,¹⁴-¹⁶ is recommended, ideally commencing early in pregnancy (e.g at booking) and continued until 36 weeks. Calcium supplementation (1.5 g/day)¹-³ is useful in women whose diet is deficient in calcium.

There is a SOMANZ¹ and National Collaborating Centre for Women’s and Children’s Health (NCC-WCH)² consensus regarding classification of the degree of hypertension, but similar classification of pre-eclampsia is controversial. The recent International Society for the Study of Hypertension in Pregnancy (ISSHP) statement suggested there was general consensus that factors determining severity include difficulty in controlling blood pressure and deteriorating clinical condition including HELLP (Haemolysis, Elevated Liver enzymes and Low Platelets) syndrome, impending eclampsia, worsening thrombocytopenia or worsening fetal growth restriction while there is less concern regarding increasing proteinuria.³ The NCC-WCH guideline defines severe pre-eclampsia as pre-eclampsia with severe hypertension and/or with symptoms, and/or biochemical and/or haematological impairment.²

**HELLP syndrome** represents a subset of women with severe preeclampsia characterised by Haemolysis, Elevated Liver enzymes (transaminases) and Low Platelets with or without other pre-eclamptic features.

Management of hypertensive disorders of pregnancy is largely dependent on severity, gestation and other coexisting maternal conditions and includes blood pressure control, fetal surveillance and monitoring for...
associated complications.

**Index of chapters**

**Quick reference practice recommendations**

1. **Hypertension in pregnancy**
   1.1 Medication options for managing mild to moderate hypertension
   1.2 Medication options for managing of severe hypertension
   1.3 Maternal investigations and fetal surveillance
   1.4 Transfer of care in pregnancy

2. **Pre-eclampsia**
   2.1 Assessment and investigation
   2.2 Transfer of care
   2.3 Management of pre-eclampsia
      2.3.1 Seizure prophylaxis
      2.3.2 Intrapartum blood tests in severe preeclampsia
      2.3.3 Fetal maturation
      2.3.4 Fluid balance
      2.3.5 Birth plan
      2.3.6 Post birth management
      2.3.7 Discharge and follow-up

3. **Eclampsia**
   3.1 Resuscitation
   3.2 Prevention of seizures
   3.3 Control of high blood pressure
   3.4 Monitoring and investigation
   3.5 Birth timing and mode
   3.6 Post birth management
   3.7 Discharge and follow-up

4. **Eclampsia flowchart**

5. **Levels of evidence**

6. **References**
<table>
<thead>
<tr>
<th>Clinical practice recommendations</th>
<th>Section Detail</th>
<th>Evidence level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consider treatment of mild to moderate hypertension in the range 140-160 / 90-100 mm Hg.</td>
<td>1.1</td>
<td>Consensus</td>
</tr>
<tr>
<td>Advise women at mod-high risk of pre-eclampsia to initiate low dose aspirin (ideally 150 mg) before 16 weeks, and continue until 36 weeks.</td>
<td>N/A</td>
<td>I</td>
</tr>
<tr>
<td>Commence antihypertensive treatment in severe hypertension, defined as a SBP greater than or equal to 160 mmHg with or without DBP greater than or equal to 110 mmHg.</td>
<td>1.2</td>
<td>I</td>
</tr>
<tr>
<td>Admit women with a SBP greater than or equal to 170 mmHg with or without DBP greater than or equal to 110 mmHg for urgent assessment and management.</td>
<td>1.2</td>
<td>I</td>
</tr>
<tr>
<td>Aim for a sustained and gradual reduction in BP in the control of severe hypertension to a SBP of less than 150 mmHg and DBP 80-100 mmHg.</td>
<td>1.2</td>
<td>Consensus</td>
</tr>
<tr>
<td>Dipstick testing is an appropriate screening test. Do a spot urine protein:creatinine ratio (PCR) for confirmation or exclusion of proteinuria when preeclampsia is suspected.</td>
<td>1.3</td>
<td>Consensus</td>
</tr>
<tr>
<td>It is not necessary to repeat assessment of proteinuria once significant proteinuria is confirmed.</td>
<td>1.3</td>
<td>Consensus</td>
</tr>
<tr>
<td>The frequency, intensity and modality of fetal evaluation (including by umbilical artery Doppler) will depend on individual maternal and fetal characteristics.</td>
<td>1.3</td>
<td>Consensus</td>
</tr>
<tr>
<td>Administer betamethasone (Celestone Chronodose®), as two intramuscular (IM) doses of 11.4 mg, 24 hours apart to promote fetal lung maturation and reduce the risk of intraventricular hemorrhage, at gestations less than 34 weeks and consider up to 37 weeks especially where caesarean section is planned. Administration should not delay birth in severe cases of pre-eclampsia/eclampsia.</td>
<td>2.3.3</td>
<td>I</td>
</tr>
<tr>
<td>Prompt caesarean section may be indicated following an eclamptic seizure and in cases of severe pre-eclampsia once the mother has been stabilised.</td>
<td>2.3.5</td>
<td>Consensus</td>
</tr>
<tr>
<td>Magnesium sulfate is the anticonvulsant of choice for the prevention and control of eclampsia.</td>
<td>2.3.1</td>
<td>I</td>
</tr>
<tr>
<td>Assess for oliguria (urine output &lt; 80 mL in 4 hours) at 4 hourly intervals in women with pre-eclampsia and eclampsia in the intrapartum and the immediate postpartum period.</td>
<td>2.3.4</td>
<td>Consensus</td>
</tr>
<tr>
<td>Ergometrine (including Syntometrine®) is not recommended in active third stage management.</td>
<td>2.3.5</td>
<td>Consensus</td>
</tr>
</tbody>
</table>
Postnatal women with a BP of less than 150/100 are suitable for discharge and follow-up in the community. This will depend on the woman’s clinical factors.

### 1. Hypertension in pregnancy

#### Classification of hypertension in pregnancy

The classification of hypertension in pregnancy below is recognised by both SOMANZ¹ and NCC-WCH² for the purpose of guideline implementation.

<table>
<thead>
<tr>
<th>Degree of hypertension</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure range</td>
<td>140/90 to 149/99</td>
<td>150/100 to 159/109</td>
<td>160/110 or higher</td>
</tr>
</tbody>
</table>

Elevations of both SBP and DBP have been associated with adverse maternal and fetal outcomes.

#### Treatment of mild to moderate hypertension

There is controversy regarding the need to treat mild to moderate hypertension in women with pre-eclampsia. Antihypertensive therapy does not prevent pre-eclampsia or the associated adverse perinatal outcomes, but it decreases by half the incidence of development of severe hypertension among women with mild hypertension.

Arguments against treatment include that there is little risk to the mother in having relatively mild hypertension for a short time; that fetal perfusion is dependent upon adequate maternal BP; and that lowering BP suppresses an important sign of the severity or progression of pre-eclampsia. Uncontrolled hypertension is however, a frequent trigger for expediting birth and controlling hypertension may allow prolongation of pregnancy. In addition, it is possible that treatment of even mild-moderate hypertension will lead to a clinically relevant reduction in the risk of pre-eclampsia and fetal or neonatal death, particularly early pregnancy loss.

In the absence of compelling evidence, consider treatment of mild to moderate hypertension in the range 140-160 / 90-100 mmHg. The CHIP trial suggests this is safe.¹⁷

#### Treatment of severe hypertension

This guideline recommends that antihypertensive treatment is to be commenced in all women with a SBP greater than or equal to 160 mm Hg and or a DBP greater than or equal to 110 mm Hg because of the risk of maternal intracerebral haemorrhage and eclampsia.¹

#### Severe hypertension requiring urgent treatment (SBP 170 mmHg)

This is defined as a SBP greater than or equal to 170 mmHg with or without DBP greater than or equal to 110 mmHg. This represents a level of BP above which the risk of maternal morbidity and mortality is increased. This degree of hypertension requires urgent assessment and management. Increasing evidence exists that cerebral perfusion pressure is altered in pregnant women making them more susceptible to cerebral haemorrhage, posterior reversible encephalopathy syndrome and hypertensive encephalopathy.

The objective in controlling hypertension in pregnancy is for a sustained and gradual reduction in BP to a
SBP of less than 150 mmHg and a DBP of 80-100 mmHg.
1.1 Medication options for managing mild to moderate hypertension

Target BP should be a SBP of less than 150 mmHg and a DBP of 80-100 mmHg.

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dose (all oral route)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methyldopa</td>
<td>250-750 mg tds</td>
<td>Slow onset of action over 24 hrs. May cause dry mouth, sedation, blurred vision. Use with caution in women with a history of depression. Avoid postpartum for this reason.</td>
</tr>
<tr>
<td>Labetalol</td>
<td>100-400 mg QID</td>
<td>Bradycardia, bronchospasm, headache, nausea and scalp tingling which usually resolve within 24 hours. Use with caution in women with a history of asthma.</td>
</tr>
<tr>
<td>Nifedipine XR (slow release)</td>
<td>20-60 mg bd</td>
<td>Severe headache in first 24 hours. Flushing, tachycardia, peripheral oedema, constipation.</td>
</tr>
<tr>
<td>Hydralazine</td>
<td>25-50 mg tds</td>
<td>Flushing, headache, nausea, lupus-like syndrome. Where oral hydralazine is contemplated it is likely to be in the setting of resistant HT on multiple other oral agents and senior input is therefore mandatory before commencing oral hydralazine.</td>
</tr>
</tbody>
</table>

Postnatal medication:

Though angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers are contraindicated in pregnancy, Enalapril is particularly appropriate in postnatal women with pre-existing hypertension who will continue on an agent long term. Caution should be exercised where renal impairment exists as ACEi use can further impair renal function. From evidence available; in most cases enalapril is clearly the agent of choice, 2.5 mg- 5 mg daily. It does not appear to negatively impact on a 'term' baby or lactation and therefore it should be our main ACE inhibitor preference. Other ACEIs have less supportive evidence (particularly with neonatal exposure via breastmilk) and should be avoided at this time. Please seek advice from Monash Medicines in this regard. Telephone: 9594 2361 Mon-Fri 9am-5pm.

1.2 Medication options for managing severe hypertension

Treatment objective: Commence treatment promptly aiming for a sustained and gradual reduction in BP to a SBP of less than 150 mmHg and a DBP of 80-100 mmHg. Care should be taken to avoid a precipitous fall in BP after antihypertensive treatment, as this may impair maternal and or placental perfusion with the attendant fetal and maternal consequences.
<table>
<thead>
<tr>
<th>Medicine</th>
<th>Dose / route</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV Fluid bolus</td>
<td>Consider administering 250 - 500 mL of crystalloid IV (e.g. sodium chloride 0.9%) or compound sodium lactate (Hartmann’s solution®) over 15 minutes prior to the administration of the first dose of hydralazine.</td>
<td>May be helpful in reducing the risk of maternal hypotension but fetal benefit unclear.</td>
</tr>
<tr>
<td>Nifedipine (oral)</td>
<td>Administer 10-20 mg nifedipine stat. Repeat as required after 45 mins (maximum dose 40 mg).</td>
<td>Oral medication of choice. Onset of action 30-45 min.</td>
</tr>
<tr>
<td>Medication</td>
<td>Dosage Instructions</td>
<td>Observations</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| **Labetalol (IV)** | - **Bolus dose:**  
  - Intermittent bolus dose of 20 mg undiluted, IV, over 2 minutes.  
  - Repeat as required after 10 mins, up to 4 times (max dose 80 mg).  
  
  **Bolus IV labetalol must be administered by medical staff**  
  
  **Continuous infusion via syringe pump (undiluted):**  
  - Consider if blood pressure still uncontrolled after 4 bolus doses (80 mg).  
  - Start at 20 mg/hr.  
  - Increase infusion rate as required by 20 mg/hr every 20 minutes until the optimum BP achieved or the maximum rate is reached (160 mg/hr). | Maximum effect within 5 minutes after each dose.  
**Observations:**  
Continuous CTG monitoring.  
Observations every 5 minutes during bolus doses.  
Observations every 15 minutes during continuous infusion until stable over one hour, then hourly. |
| **Labetalol (oral)** | 200 - 400 mg QID.                                                                                                                                                                                                       | Consider the oral regime if appropriate.                                                             |
| **Hydralazine (IV)** | - **Bolus dose (20 mg hydralazine in 20 mL sodium chloride 0.9%, (1 mg/mL)):**  
  - Administer 5 - 10 mg (5-10 mL) IV, over 5 minutes.  
  - Repeat dose as required every 20 minutes, until target BP achieved (max dose 30 mg).  
  
  **Note:** **Bolus IV hydralazine must be administered by medical staff.**  
  
  **Continuous infusion via syringe pump (40 mg hydralazine in 40 mL sodium chloride 0.9%, (1 mg/mL):**  
  - Consider if BP is still uncontrolled after 30 mg IV hydralazine.  
  - Start infusion rate at 10 mg/hr.  
  - Increase infusion rate (if required) by 2 mg/hr, every 20 minutes until the target BP achieved or the maximum rate (20 mg/hr) reached. | Smooth muscle dilator.  
Maternal side effects: headache, tachycardia, palpitations, gastrointestinal disturbance, flushing, hypotension.  
**Observations:** as per IV labetalol above. |
In addition to the antihypertensive regime, admitted women with acute severe hypertension (SBP >170 mmHg) require:
- two large bore IV cannulas
- continuous CTG
- indwelling urinary catheter burette to aid hourly measurements
- half hourly maternal observations.

1.3 Maternal investigations and fetal surveillance

The following are the recommendations for maternal investigations and fetal surveillance in women with hypertension in pregnancy.

<table>
<thead>
<tr>
<th>Maternal investigations</th>
<th>Fetal surveillance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic hypertension</td>
<td>Organise early dating ultrasound in first trimester.</td>
</tr>
<tr>
<td>At each visit, assess for proteinuria*</td>
<td>US for fetal growth/amniotic fluid index (AFI)/Doppler in 3rd trimester; repeat as indicated.</td>
</tr>
<tr>
<td>If sudden increase in BP or new proteinuria, perform pre-eclampsia blood screen.**</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gestational hypertension</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Assess for proteinuria at each visit.</td>
<td>US for fetal growth/AFI/Doppler at time of diagnosis</td>
</tr>
<tr>
<td>Perform bloods for pre-eclampsia screen 4 weekly or as indicated.</td>
<td>- Repeat every 3-4 weeks.</td>
</tr>
</tbody>
</table>

* Urinalysis by dipstick followed by spot urine PCR if ≥1+ proteinuria noted.

Note: Once significant proteinuria has been detected, there is no established role for serial testing as the severity or progress of proteinuria should not alter management decisions.

** Pre-eclampsia blood screen
- full blood examination (FBE)
- urea, electrolytes and creatinine (UEC)
- liver function (LFT)
- uric acid (UA) +/- coagulation studies if clinically indicated (e.g. if platelets < 100 x10^9/L, abnormal LFT’s or falling Hb).

1.4 Transfer of care (pregnancy)

Hypertension, of any classification, is an exclusion for midwife led care and shared care affiliate. Women developing hypertension during pregnancy are to be referred to specialist obstetrician care, as per local procedures, for the remainder of their pregnancy.
2. **Pre-eclampsia**

2.1 Assessment and investigation

*Initial assessment and investigations (should be performed in hospital):*

**Maternal assessment**

- Take a thorough history, with particular enquiry about pre-eclampsia symptoms (e.g. headache, visual disturbance, epigastric or right upper quadrant pain).
- Vital signs: BP, pulse rate (PR), respiratory rate (RR) and temperature. [Note: correct BP cuff size is important].
- General examination, including abdominal palpation (fetal lie, presentation, size) and neurological examination.

**Maternal investigations**

- Urinalysis +/- mid-stream urine and spot urine protein: creatinine ratio (if FWT ≥ 1+ proteinuria).
- Pre-eclampsia biochemical screen (Full blood examination (FBE), Urea, electrolytes and creatinine (UEC), Liver function tests (LFT), Uric acid (UA) +/- clotting).

**Fetal assessment (depending on gestational age) may include:**

- CTG (> 28 weeks gestation).
- Ultrasound:
  - Fetal biometry
  - Amniotic Fluid Index (AFI)
  - Fetal Doppler studies (including umbilical artery, middle cerebral artery +/- ductus venosus)
  - Biophysical profile (BPP).

**Ongoing outpatient maternal and fetal surveillance**

<table>
<thead>
<tr>
<th>Maternal investigations</th>
<th>Fetal surveillance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pre-eclampsia</strong></td>
<td>Assess for proteinuria only at time of diagnosis and do not repeat once significant proteinuria is confirmed.</td>
</tr>
<tr>
<td></td>
<td>Perform weekly pre-eclampsia bloods (or more frequently if indicated)</td>
</tr>
<tr>
<td></td>
<td>Weekly pregnancy care clinic.</td>
</tr>
<tr>
<td></td>
<td>Continue surveillance (BPP, Doppler's) weekly.</td>
</tr>
<tr>
<td></td>
<td>Or, if IUGR is noted (as per guideline).</td>
</tr>
<tr>
<td></td>
<td>CTG twice weekly.</td>
</tr>
</tbody>
</table>

Should investigation and surveillance need to be more intensive and frequent than the above recommendations, based upon gestation, severity and rate at which the condition progresses, inpatient admission is likely to be warranted. Women diagnosed with pre-eclampsia who have outpatient monitoring
need to be educated regarding the progressive nature of pre-eclampsia and present promptly for assessment should she develop pre-eclamptic symptoms.

2.2 Transfer of care

Admitted women with pre-eclampsia, including those on magnesium sulfate, may require transfer to another hospital so as to optimise the outcome for either or both mother and fetus. A decision regarding transfer is largely dependent on gestation, maternal condition, staffing level, site capacity and resources. Any such decision is to be made in consultation with senior medical staff at the respective transferring and receiving hospitals.

2.3 Management of pre-eclampsia

Hypertension should be controlled in women with pre-eclampsia as per the recommendations above for management of hypertension in pregnancy.

In labour, regional anaesthesia can be a useful adjunct for lowering of blood pressure and should be taken into account when administering antihypertensives.

2.3.1 Seizure prophylaxis

Magnesium sulfate is recommended for seizure prophylaxis in women with pre-eclampsia where required.\(^1\-^3\)

Refer: Magnesium sulfate administration (Maternity).

2.3.2 Intrapartum - blood tests in severe preeclampsia

Consider intermittent pre-eclampsia blood tests in labouring women with severe pre-eclampsia and in those on magnesium sulfate if appropriate. This can be performed at a frequency based on the woman’s clinical circumstance.

2.3.3 Fetal maturation

Betamethasone (Celestone Chronodose\(^\text{®}\)), given as two IM doses of 11.4 mg, 24 hours apart, is indicated to promote fetal lung maturation and reduce the risk of intraventricular hemorrhage in preterm (below 34 weeks, and up to 37) neonates.\(^4\-^7\)

The evidence is strongest at gestations below 35 weeks but it is also recommended at gestations below 37 weeks where a caesarean section is planned.\(^4\-^7\) Administration should not delay birth in severe cases of pre-eclampsia or eclampsia.

Magnesium sulfate for fetal neuroprotection should be considered for all women less than 30 weeks gestation in whom birth is imminent within the next 24 hours.\(^1\,^8\)

2.3.4 Fluid balance
Hypertensive disorders in pregnancy pre-eclampsia/eclampsia Clinical Guideline

Careful maternal fluid balance is required in all women with pre-eclampsia.

In **severe pre-eclampsia** maternal fluid retention can lead to severe acute pulmonary oedema. Strict fluid balance is imperative to avoid risk of fluid overload. Fluid input should be restricted to normal requirements, which is usually about 80 mL/hr or 1 mL/kg/hr. Urine output should be measured and recorded every hour, via an indwelling urinary catheter (IDC) with an hourly urometer.

Where urine output is < 80 mL in total over 4 consecutive hours, medical review is necessary to assess renal function. It is important to know that oliguria in the intrapartum and immediate post-partum period is common and physiological. Fluid therapy is unnecessary unless there is evidence of renal impairment (such as a rising serum creatinine).

In the presence of sustained oliguria and renal impairment consider transfer to HDU / ICU for more intensive haemodynamic monitoring. Diuretic use should be avoided in the absence of pulmonary oedema.

### 2.3.5 Birth plan

**Timing of birth**

As the only definitive treatment for pre-eclampsia is to birth, careful consideration should be given to the timing in women with this condition. This can be a difficult decision as the prognoses for mother and fetus are generally opposing with prolongation of pregnancy.

At gestations < 34 weeks, if the maternal and fetal condition permits, stabilise the maternal condition with expectant management to enable corticosteroids to take effect and minimise the risks of prematurity for the fetus.

Birth is recommended where:
- gestation > 37 weeks
- inability to control hypertension
- severe pre-eclampsia (deteriorating organ function)
- neurological complications (including eclampsia)
- pulmonary oedema
- non-reassuring fetal status.

**Mode of birth**

The mode of birth is dependent on factors such as fetal and maternal condition, gestation, cervical dilatation and anticipated time interval. Generally, prompt birth by caesarean section is indicated following an eclamptic seizure and in cases of severe pre-eclampsia following maternal stabilisation. Without these acute emergency situations, induction and / or augmentation of labour should be considered.

Oxytocin (Syntocinon®) 10 units IM or 5 units by a ‘slow’ IV bolus is recommended for active management of the third stage of labour. Ergometrine (including Syntometrine®) should be avoided.

### 2.3.6 Post birth management

It is reasonable to expect that the woman’s condition will steadily improve following birth. However in
addition to routine postpartum management, women with hypertensive disease in pregnancy need:

- Blood pressure control with anti-hypertensive therapy (target BP < 140/90 mmHg). See: Postnatal medication.
- Monitoring of deranged biochemistry.

In situations where magnesium sulfate has been given for seizure prevention the infusion should continue for 24 hours after birth. Strict fluid balance should also be maintained until a good diuresis has occurred.

Debriefing regarding the birth should include counselling about future risk of recurrence in subsequent pregnancies, as well as hypertension and cardiovascular disease risks in later life. Emphasis should be placed on weight management, healthy lifestyle and appropriate referral to obstetric-led care for subsequent pregnancies. Reduce antihypertensive(s) if the blood pressure falls below 120/80.

2.3.7 Discharge and follow-up

Suitability for discharge to community care should take into account blood pressure control, evidence of resolving biochemical derangement and usual postpartum issues (e.g. feeding, lochia and pain management). The timing of discharge is to be made in consultation with senior obstetric staff. Women with a blood pressure reading of 149/99 or lower are suitable for discharge and follow-up in the community.

Women with severe pre-eclampsia, eclampsia or other complicated cases of hypertensive disorders should be reviewed 6-8 weeks post-discharge. This can happen at the outpatient clinic at the hospital or with the woman’s GP or specialist obstetrician in their private rooms. In general, women with severely preterm birth, eclampsia or need for ICU, intrapartum magnesium sulfate should be seen by a senior registrar or consultant obstetrician for their postnatal review.

3. Eclampsia

There are four main aspects to care of the woman who sustains eclampsia: resuscitation, prevention of further seizures, control of hypertension and birth.

3.1 Resuscitation

Call for HELP

Protect the woman from harm and move her to the recovery position. These seizures are usually self-limiting.

Consider the need for a Code Pink, MET call or Code Blue according to the clinical situation.

Magnesium sulfate is definitely the anticonvulsant of choice for treatment of eclampsia. However, a prolonged, generalized seizure may be due to other intracerebral pathology (e.g. haemorrhage secondary to uncontrolled hypertension) in which case, benzodiazepines are appropriate. Consider intravenous diazepam (2 mg/min to a maximum of 10 mg) or clonazepam (1-2 mg over 2-5 mins).1

Following cessation of the seizure:

- Check the airway and clear if necessary.
- Check for breathing and if present administer oxygen.
- Check the respiratory rate, oxygen saturations, BP and pulse rate.
Obtain IV access.

3.2 Prevention of seizures

Magnesium sulfate is the anticonvulsant of choice for the prevention of eclamptic seizures.\(^1\)-\(^3\)

Monash Health uses pre-mixed IV bags of 25 g magnesium sulfate in 50 mL water for injection. Following appropriate resuscitation, commence treatment with magnesium sulfate given as a 4 g loading dose over 20 minutes, followed by an infusion of 1 g/hr.

In the event of further seizure(s), an additional 2 g of magnesium sulfate is to be given IV over 10 minutes for each episode. The magnesium sulfate infusion rate may be increased to 2-3 g/hr.

- See: Magnesium sulfate administration (Maternity) procedure.
- Continue the magnesium sulfate maintenance infusion for 24 hours following birth or the last eclamptic seizure.

3.3 Control of hypertension

As per 1.1.1 with target BP < 150/80-100 mmHg

3.4 Monitoring and investigations

3.4.1 Maternal monitoring

- As per Magnesium sulfate administration (Maternity) procedure.
- Additional attention should be given to uterine activity, neurological irritability and signs of coagulopathy or haemorrhage.
- Document all observations and fluid balance on the Maternity Intensive Observation and Fluid Balance Chart (MRF30).

3.4.2 Fetal monitoring

- When the eclamptic seizure has ceased, and the maternal condition including blood pressure is stable, consider applying a cardiotocograph (CTG) and performing further fetal assessment as required.

3.5 Birth – timing and mode

As per 2.3.5

3.6 Post birth management

As per 2.3.6

3.7 Discharge and follow up

As per 2.3.7

- It is important to consider other causes for seizures in pregnancy after stabilization of the patient. Differential diagnoses for similar presentations include epilepsy, intracranial haemorrhage, meningitis, cerebral venous thrombosis, space-occupying lesions, metabolic disorders, head trauma and drug or alcohol-related issues.
Persistent neurological symptoms merit imaging of the brain and appropriate referral.
4 Eclampsia Flowchart

Immediate management
Call for help.
During seizure: protect the woman from harm and position her in the recovery position.

Airway: ensure airway is clear.

Breathing: if breathing give high flow O₂, check RR and SaO₂

Circulation: BP, pulse, obtain IV access.
Consider the need for a Code Pink, MET call or Code Blue according to the clinical situation.

Loading dose of magnesium sulfate
(see Magnesium sulfate administration procedure)
Magnesium sulfate 4 g IV over 20 mins.

Maintenance dose
Magnesium sulfate 1 g/hr IV for 24 hrs.

For recurrent seizures
Further magnesium sulfate 2 g IV over 10 mins.
Consider increasing the infusion rate to 2-3 g/hr.
Continue magnesium sulfate for 24 hours following birth or the last eclamptic seizure.

Seizure control

Treat hypertension if: SBP = or > 160 and DBP = or > 110

During pregnancy aim for SBP (< 150 mmHg) and DBP (80 - 100 mmHg)
Consider 250 -500 mL initial IV fluid bolus if appropriate.
Administer either:
• Labetalol 20 mg IV bolus over 2 mins. Repeat as required every 10 mins. Maximum dose 80 mg. Or
• Nifedipine Oral 10-20 mg stat. Repeat as required after 45 mins (maximum dose 40 mg). Or
• Hydralazine IV 5-10 mg (5-10 mL), over 5 minutes. Repeat same dose as required every 20 minutes, until target BP achieved (max dose 30 mg).

Consider maintenance infusion of either labetalol or hydralazine.
(Refer control of hypertension in preeclampsia)
Combination therapy may be required to control hypertension.

Investigation

Once seizure has passed:
Ongoing management of ABC
Maternal ongoing observations:
• 5 minutely BP if unstable
• once stable, hourly observations including neurological.
Maternal investigations:
• FBE, U&E, LFT, Uric acid
• G&H
• clotting if platelets 100 x 10⁹/L.
Fetal assessment
• CTG.

Control Hypertension

Resuscitate

If pregnant, expedite birth

Once eclampsia has occurred, expedite the birth.
Stabilise the mother first.
Mode of birth depends on both maternal and fetal wellbeing, fetal presentation, gestation and cervical favourability.
Obstetric team to liaise with anaesthetic, neonatal and ICU/HDU teams.
### Levels of evidence

<table>
<thead>
<tr>
<th>Level</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A systematic review of level II studies.</td>
</tr>
<tr>
<td>II</td>
<td>A randomised controlled trial.</td>
</tr>
<tr>
<td>III-1</td>
<td>A pseudo-randomised controlled trial.</td>
</tr>
</tbody>
</table>
| III-2 | A comparative study with concurrent controls:  
|       | - non-randomised experimental trial  
|       | - cohort study  
|       | - case-control study.  
|       | Interrupted time series without a parallel control group. |
| III-3 | A comparative study without concurrent controls:  
|       | - historical control study  
|       | - two or more single arm study.  
|       | Interrupted time series without a parallel control group. |
| IV    | Case series with either post-test or pre-test outcomes. |

*Refer to full reference for the evidence hierarchy of prognosis, aetiology and screening interventions.

**Consensus:** An additional level of evidence used here, for example, from published guidelines that have involved extensive consultation and deliberation, where specific recommendations have been agreed upon by consensus of the contributors.

---

### References:


Retrieved from: [http://www.bmj.com/content/bmj/355/bmj.i5044.full.pdf](http://www.bmj.com/content/bmj/355/bmj.i5044.full.pdf)


Hypertensive disorders in pregnancy pre eclampsia/eclampsia Clinical Guideline

Related resources

Eclampsia box contents - Implementation Tool

Keywords or tags

PIH, PET

Document Management


Person accountable for clinical content:

A/Prof Ryan Hodges, Program Director of Women’s & Newborn and Head of Obstetrics | Monash Health

Staff consulted in the development/endorsement of the clinical guideline occurred with:

Vangy Malkoutzis, Anaesthetic Consultant | Monash Health 2015
Nicole Dirnbauer, Assistant Deputy Director of Pharmacy - Quality Support and Development Services | Monash Health, 2015, 2017
Joanne C Mockler, Research Midwife Consultant/Manager, Perinatal (Obstetric) Clinical Trials, Monash Health and Monash University 2017
Rodney Whyte, Therapeutic Medicines Specialist (Medicines Information) Monash Health, July 2017
Dr Daniel L Rolnik, Obstetrician and Gynaecologist / Fetal Medicine Specialist | Monash Health, July 2017
Maternity Guideline Development Group 2015, 2017

Policy supported: Evidence-based clinical care.

Executive sponsor: Chief Operating Officer

If this is a hard copy it might not be the latest version of this document. Please see the Monash Health site for current documents.


Retrieved from: https://www.karger.com/Article/Pdf/336662


Disclaimer

The maternity clinical practice procedures and guidelines have been developed having regard to general circumstances. It is the responsibility of every clinician to take account of both the particular circumstances of each case and the application of these procedures and guidelines. In particular, clinical management must always be responsive to the needs of the individual woman and particular circumstances of each pregnancy.

These procedures and guidelines have been developed in light of information available to the authors at the time of preparation. It is the responsibility of each clinician to have regard to relevant information, research or material that may have been published or become available subsequently. Please check this site regularly for the most current version.